Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Non-Current Assets (2021 - 2025)

Historic Other Non-Current Assets for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $2.5 million.

  • Amylyx Pharmaceuticals' Other Non-Current Assets rose 41867.22% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 41867.22%. This contributed to the annual value of $24000.0 for FY2024, which is 9657.63% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Other Non-Current Assets of $2.5 million as of Q3 2025, which was up 41867.22% from $11000.0 recorded in Q1 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Other Non-Current Assets registered a high of $2.5 million during Q3 2025, and its lowest value of $11000.0 during Q1 2025.
  • For the 5-year period, Amylyx Pharmaceuticals' Other Non-Current Assets averaged around $559666.7, with its median value being $466000.0 (2022).
  • Over the last 5 years, Amylyx Pharmaceuticals' Other Non-Current Assets had its largest YoY gain of 41867.22% in 2025, and its largest YoY loss of 9776.88% in 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $200000.0 in 2021, then soared by 133.0% to $466000.0 in 2022, then soared by 50.43% to $701000.0 in 2023, then tumbled by 96.58% to $24000.0 in 2024, then soared by 10316.67% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $11000.0 for Q1 2025, and $24000.0 during Q4 2024.